Europe Intradermal Injections Market

The intradermal injections market in Europe is expected to grow from US$ 1,029.42 million in 2021 to US$ 2,131.06 million by 2028. It is estimated to grow at a CAGR of 11.0% from 2021 to 2028. 

Increasing Incidence of Communicable and Noncommunicable Diseases Boost Market Growth

The incidence of several communicable and noncommunicable diseases has increased exponentially in the last few years, mainly due to the unhealthy lifestyle of the modern world. Smoking, infections, and genetic factors can cause serious respiratory complications, cardiovascular disorders, and bacterial and viral infections, etc. These diseases are among the medical conditions exerting a huge burden on the public healthcare system in various countries. Per the data by the WHO, ~10 million cases of tuberculosis are observed every year and all of them are diagnosed using a tuberculin skin test, which involves the use of intradermal injections. Several studies suggest that intradermal injections could improve the absorption of various anticancer and immunological drugs, and they can also be used to deliver gene therapies. Tropis ID of Pharmajet, one of the Novel intradermal injection devices, offers prominent results in delivering various drugs targeting a wide range of diseases.

Market Overview

The UK, Germany, France, Italy, Spain, and the Rest of Europe are the key contributors to the intradermal injections market in Europe. Germany dominates the market in this region. Various medical players in Germany manufacture cost-effective products with superior quality. Germany is the second largest market for medical devices after the US. According to AIM, an IGES Group company, the medical device market in Germany is valued at US$ 28.25 billion (25 billion euros). Additionally, the government in the country has made health insurance mandatory for citizens. ~71.4 million people in Germany are covered by Gesetzliche Krankenversicherung (GKV), which is a public health insurance, and ~8.8 million people are covered by the Private Krankenversicherung (PKV) through state aid, which is a private health insurance. According to the WHO data, the detection rate of tuberculosis cases was ~87% in 2020. Further, the incidence rate of tuberculosis in Germany is ~5.5 per 100,000 population, which indicates the elevating need for intradermal injections. The expanding elderly population and the rising prevalence of allergic reactions are also propelling the German market for intradermal injections. The country has more than 400 hospitals dedicated to the geriatric population. Therefore, the demand for advanced medical equipment, such as needle-free injections, is high in this country. With the high acceptance of cosmetic procedures, the use of intradermal injections in aesthetic procedures is also on rise in the country. Grabbing these opportunities, Germany invests significantly in healthcare research and infrastructure. According to Eurostat, the healthcare expenditure in Germany accounted for US$ 394.9 million in 2015. Along with this, various leading companies are investing in medical device manufacturing in Germany.

Europe Intradermal Injections Market Revenue and Forecast to 2028 (US$ Million)

Europe Intradermal Injections Strategic Insights

Strategic insights for the Europe Intradermal Injections provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Europe Intradermal Injections Report Scope

Europe Intradermal Injections Regional Insights

The geographic scope of the Europe Intradermal Injections refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

The Europe intradermal injections market is segmented on the basis of method, application, end user, and country. 

Based on method, the market is segmented into normal sized needle, short needle, and without needle. The normal sized needles segment registered the largest market share in 2021. The normal sized needles segment is further sub segmented into intradermal microinjections, microneedle arrays, and tattoo devices. The short needle segment is bifurcated into intradermal liquid jet injectors and ballistic intradermal injectors. 

In terms of application, the Europe intradermal injections market is segmented into tuberculin skin test, allergy test, local aesthetics, and others. The tuberculin skin test segment held the largest market share in 2021. 

The Europe intradermal injections market, by end user, is segmented into hospitals, diagnostic laboratories, academics and research institutes, and others. The hospitals segment held the largest market share in 2021. 

Based on country, the market is segmented into the UK, Germany, France, Italy, Spain, and rest of Europe. Germany dominated the market in 2021. 

BD; West Pharmaceutical Services, Inc; Terumo Corporation; Nanopass; PharmaJet; Idevax; EUNSUNG GLOBAL; Crossject; Cardinal Health Inc; and Hindustan Syringes and Medical Devices Ltd are the leading companies operating in intradermal injections market in the Europe region.